Tag: head and neck cancer
#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer
1. Pembrolizumab-alone or pembrolizumab-chemotherapy prolonged overall survival vs cetuximab-chemotherapy in the PD-L1 positive population 2. While pembrolizumab-chemotherapy found an improved ...
#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
Click to read this study in JAMA Otolaryngology - Head & Neck Surgery.
#VisualAbstract: Tislelizumab significantly improves survival outcomes in advanced or metastatic esophageal squamous cell carcinoma
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Induction chemotherapy with cisplatin plus gemcitabine in addition to concurrent chemotherapy improves survival for nasopharyngeal carcinoma
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Once-weekly cisplatin is noninferior to cisplatin every 3 weeks for postoperative head and neck cancers
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma
Click to read this study in JAMA Oncology.
#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
Click to read this study in the Journal of Clinical Oncology.
#VisualAbstract: Upper neck irradiation is noninferior to whole neck irradiation for newly diagnosed nasopharyngeal carcinoma
Click to read this study in The Lancet Oncology.
#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression
Click to read this study in The Lancet Oncology.
